

Author index

Volume 29 (1996)

Andreoni, M., see Jacobsen, H. 29, 95
 Andreoni, M., see Vella, S. 29, 91
 Anné, J., see Esté, J.A. 29, 297
 Anné, J., see Vreese, K.D. 29, 209

Bahlman, W., Innovative combination clinical trial designs/
 patient compliance: A community perspective 29, 115
 Baldoni, J., see Black, P.L. 29, 175
 Barney, S., see Black, P.L. 29, 175
 Baruch, A., see Collier, A.C. 29, 99
 Bassett, R., see Collier, A.C. 29, 99
 Benoit, S., see McLaren, C. 29, 119
 Biron, F., F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F.
 Nugier, J. Grange, S. Malley, F. Hamed-Sangsari,
 Black, P.L., M.A. Ussery, S. Barney, R. Wittrock, P. De-
 Marsh, G.B. Dreyer, S.R.P. Jr., P. DalMonte, J. Baldoni,
 Blum, M.R., see Clair, M.H.S. 29, 53
 Boucher, C.A.B., see Jong, M.D.d. 29, 5
 Bridger, G., see Esté, J.A. 29, 297
 Bridger, G.J., see Vreese, K.D. 29, 209
 Bruggeman, C.A., see Stals, F.S. 29, 61
 Bu, M., see Turpin, J.A. 29, 269
 Buckheit Jr., R.W., see Turpin, J.A. 29, 269
 Buier, R.M., see Gwaltney Jr., J.M. 29, 287

Cirelli, R., K. Herne, M. McCrary, P. Lee, S.K. Tying,
 Famciclovir: review of clinical efficacy and safety 29, 141
 Clair, M.H.S., J. Millard, J. Rooney, M. Tisdale, N. Parry,
 B.M. Sadler, M.R. Blum, G. Painter, In vitro antiviral
 activity of 141W94 (VX-478) in combination with other
 antiretroviral agents
 Clanton, D., see Turpin, J.A. 29, 269
 Clark, J.M., see Yang, H. 29, 233
 Clercq, E.D., see Jashés, M. 29, 309

Clercq, E.D., see Vreese, K.D. 29, 209
 Colacino, J.M., Review article Mechanisms for the anti-hep-
 atitis B virus activity and mitochondrial toxicity of
 fialuridine (FIAU) 29, 125

Collier, A.C., R.W. Coombs, D.A. Schoenfeld, R. Bassett, A.
 Baruch, L. Corey, Short communication Combination ther-
 apy with zidovudine, didanosine and saquinavir 29, 99
 Conte, M.P., see Marchetti, M. 29, 221
 Coombs, R.W., see Collier, A.C. 29, 99
 Coombs, R.W., see Reichelderfer, P.S. 29, 83
 Corey, L., see Collier, A.C. 29, 99
 Cundy, K.C., see Wachsmann, M. 29, 153

Daibata, M., E.-M. Enzinger, J.E. Monroe, R.E. Kilkuskie,
 A.K. Field, C. Mulder, Antisense oligodeoxynucleotides
 against the BZLF1 transcript inhibit induction of produc-
 tive Epstein-Barr virus replication 29, 243
 DalMonte, P., see Black, P.L. 29, 175
 De Clercq, E., see Esté, J.A. 29, 297
 De Vreese, K., see Esté, J.A. 29, 297
 DeMarsh, P., see Black, P.L. 29, 175
 Desmyter, J., see Esté, J.A. 29, 297
 Desmyter, J., see Vreese, K.D. 29, 209
 Drain, R.L., see Yang, H. 29, 233
 Dreyer, G.B., see Black, P.L. 29, 175
 Duncan, I., see Vella, S. 29, 91
 Duncan, I.B., see Jacobsen, H. 29, 95
 Dusheiko, G.M., Summary: antiviral treatment of hepatitis C
 virus 29, 77

Elkins, M., see McLaren, C. 29, 119
 Enzinger, E.-M., see Daibata, M. 29, 243
 Ercoli, L., see Vella, S. 29, 91
 Esté, J., see Vreese, K.D. 29, 209
 Esté, J.A., K. De Vreese, M. Witvrouw, J.-C. Schmit, A.-M.
 Vandamme, J. Anné, J. Desmyter, G.W. Henson, G.
 Bridger, E. De Clercq, Antiviral activity of the bicyclam
 derivative JM3100 against drug-resistant strains of human
 immunodeficiency virus type 1.
 Faraj, A., R.F. Schinazi, M.-Y. Xie, G. Gosselin, C. Peri-
 gaud, J.-L. Imbach, J.-P. Sommadossi, Selective protection
 of toxicity of 2',3'-dideoxypyrimidine nucleoside analogs by
 β -D-uridine in human granulocyte-macrophage progenitor
 cells 29, 261

- Field, A.K., see Daibata, M. 29, 243
 Fisher, P.E., see Wachsmann, M. 29, 153
 Franco, C.A., see Yang, H. 29, 233
 Fresard, A., see Biron, F. 29, 111
- Galasso, G.J., see Jong, M.D.d. 29, 5
 Galluzzo, C., see Vella, S. 29, 91
 Garaci, E., see Pica, F. 29, 187
 Ghanem, A.-H., see Patel, P.J. 29, 279
 Giannini, G., see Vella, S. 29, 91
 Gnann Jr, J.W., see Whitley, R.J. 29, 67
 González, M., see Jashés, M. 29, 309
 Gorton, L., see Saravolac, E.G. 29, 199
 Gosselin, G., see Faraj, A. 29, 261
 Graham, L., see Turpin, J.A. 29, 269
 Grange, J., see Biron, F. 29, 111
 Griffin, P., see Vreese, K.D. 29, 209
 Gwaltney Jr., J.M., R.M. Buier, J.L. Rogers, The influence of signal variation, bias, noise and effect size on statistical significance in treatment studies of the common cold 29, 287
- Haenggi, M., see Jacobsen, H. 29, 95
 Hamed-Sangsari, F., see Biron, F. 29, 111
 Haraguchi, Y., see Ikeda, R. 29, 163
 Hayden, F.G., Combination antiviral therapy for respiratory virus infections 29, 45
 Henson, G.W., see Esté, J.A. 29, 297
 Henson, G.W., see Vreese, K.D. 29, 209
 Herne, K., see Cirelli, R. 29, 141
 Higuchi, W.I., see Patel, P.J. 29, 279
 Hirsch, M.S., see Jong, M.D.d. 29, 5
 Hirschel, B., see Perrin, L. 29, 87
 Hoshino, H., see Ikeda, R. 29, 163
- Ikeda, R., Y. Haraguchi, Y. Ikeda, S. Kondo, T. Takeuchi, H. Hoshino, Inhibition of human immunodeficiency virus type 1 infectivity by a new amine bellenamine 29, 163
 Ikeda, Y., see Ikeda, R. 29, 163
 Imbach, J.-L., see Faraj, A. 29, 261
- Jabs, D.A., Design of clinical trials for drug combinations: cytomegalovirus retinitis — foscarnet and ganciclovir. The CMV retinitis retreatment trial 29, 69
 Jacobsen, H., see Vella, S. 29, 91
 Jacobsen, H., M. Haenggi, M. Ott, I.B. Duncan, M. Andreoni, S. Vella, J. Mous, Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials 29, 95
 James, W., see Vreese, K.D. 29, 209
 Jashés, M., M. González, M. López-Lastra, E.D. Clercq, A. Sandino, Inhibitors of infectious pancreatic necrosis virus (IPNV) replication 29, 309
 Jaffe, H.S., see Wachsmann, M. 29, 153
 Johnson, V.A., Combination therapy for HIV-1 infection—overview: preclinical and clinical analysis of antiretroviral combinations 29, 35
- Jong, M.D.d., C.A.B. Boucher, G.J. Galasso, M.S. Hirsch, E.R. Kern, J.M.A. Lange, D.D. Richman, Consensus symposium on combined antiviral therapy 29, 5
 Jr., S.R.P., see Black, P.L. 29, 175
- Kern, E.R., see Jong, M.D.d. 29, 5
 Kern, E.R., see Patel, P.J. 29, 279
 Kern, E.R., Role of animal models in selecting antiviral combinations for clinical studies 29, 57
 Kern, E.R., D.D. Richman, Consensus symposium on combined antiviral therapy 29, 3
 Kilkuskie, R.E., see Daibata, M. 29, 243
 Kloover, J.S., see Stals, F.S. 29, 61
 Kondo, S., see Ikeda, R. 29, 163
 Korba, B.E., Short communication In vitro evaluation of combination therapies against hepatitis B virus replication 29, 49
 Kournikakis, B., see Saravolac, E.G. 29, 199
- Lambert, D.M., see Black, P.L. 29, 175
 Lange, J.M.A., see Jong, M.D.d. 29, 5
 Lee, P., see Cirelli, R. 29, 141
 Lietman, P.S., see Wachsmann, M. 29, 153
 Lietman, P.S., Short communication Overview: Issues concerning the pharmacology of multiple drug regimens 29, 65
 Longhi, C., see Marchetti, M. 29, 221
 López-Lastra, M., see Jashés, M. 29, 309
 Lucht, F., see Biron, F. 29, 111
- Malley, S., see Biron, F. 29, 111
 Marchetti, M., C. Longhi, M.P. Conte, S. Pisani, P. Valenti, L. Seganti, Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells 29, 221
 McCrary, M., see Cirelli, R. 29, 141
 McLaren, C., M. Elkins, M. Salgo, M. Myers, S. Benoit, M. Warburg, Inter-Company Collaboration for AIDS Drug Development: perspective on combination studies 29, 119
 Millard, J., see Clair, M.H.S. 29, 53
 Monroe, J.E., see Daibata, M. 29, 243
 Mous, J., see Jacobsen, H. 29, 95
 Mulder, C., see Daibata, M. 29, 243
 Myers, M., see McLaren, C. 29, 119
- Nugier, F., see Biron, F. 29, 111
- Ott, M., see Jacobsen, H. 29, 95
- Painter, G., see Clair, M.H.S. 29, 53
 Palamara, A., see Pica, F. 29, 187
 Parry, N., see Clair, M.H.S. 29, 53
 Pastelak, A., see Wachsmann, M. 29, 153
 Patel, P.J., A.-H. Ghanem, W.I. Higuchi, V. Srinivasan, E.R. Kern, Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept 29, 297

- Perigaud, C., see Faraj, A. 29, 261
- Perrin, L., B. Hirschel, Combination therapy in primary HIV infection 29, 87
- Petty, B.G., see Wachsmann, M. 29, 153
- Peyramond, D., see Biron, F. 29, 111
- Pica, F., A. Rossi, N. Santirocco, A. Palamara, E. Garaci, M.G. Santoro, Effect of combined α IFN and prostaglandin A₁ treatment on vesicular stomatitis virus replication and heat shock protein synthesis in epithelial cells 29, 187
- Pirillo, M.F., see Vella, S. 29, 91
- Pisani, S., see Marchetti, M. 29, 221
- Pollard, R.B., CMV retinitis: ganciclovir/monoclonal antibody 29, 73
- Reichelderfer, P.S., R.W. Coombs, Cartesian coordinate analysis of viral burden and CD4⁺ cell count in HIV disease: implications for clinical trial design and analysis 29, 83
- Reymen, D., see Vreese, K.D. 29, 209
- Rice, W.G., see Turpin, J.A. 29, 269
- Richman, D.D., The implications of drug resistance for strategies of combination antiviral chemotherapy 29, 31
- Richman, D.D., see Jong, M.D.d. 29, 5
- Richman, D.D., see Kern, E.R. 29, 3
- Rogers, J.L., see Gwaltney Jr., J.M. 29, 287
- Rooney, J., see Clair, M.H.S. 29, 53
- Rossi, A., see Pica, F. 29, 187
- Sadler, B.M., see Clair, M.H.S. 29, 53
- Salgo, M., see McLaren, C. 29, 119
- Sandino, A., see Jashés, M. 29, 309
- Santirocco, N., see Pica, F. 29, 187
- Santoro, M.G., see Pica, F. 29, 187
- Saravolac, E.G., B. Kournikakis, L. Gorton, J.P. Wong, Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon- γ 29, 199
- Sarmati, L., see Vella, S. 29, 91
- Schaeffer, C.A., see Turpin, J.A. 29, 269
- Schinazi, R.F., see Faraj, A. 29, 261
- Schmit, J.-C., see Esté, J.A. 29, 297
- Schoenfeld, D.A., see Collier, A.C. 29, 99
- Seganti, L., see Marchetti, M. 29, 221
- Shipman, Jr., C., Analysis of drug-drug interactions: an overview 29, 41
- Sneller, M.C., Consensus symposium on combined antiviral therapy; Overview of interferon and IL-2 combinations for the treatment of HIV infection 29, 105
- Sommadossi, J.-P., see Faraj, A. 29, 261
- Soong, S.-j., see Whitley, R.J. 29, 67
- Srinivasan, V., see Patel, P.J. 29, 279
- Stals, F.S., S.S. Wagenaar, J.S. Kloover, W.Y.R. Vanagt, C.A. Bruggeman, Combinations of ganciclovir and antibody for experimental CMV infections 29, 61
- Steinkasserer, A., see Vreese, K.D. 29, 209
- Takeuchi, T., see Ikeda, R. 29, 163
- Tisdale, M., see Clair, M.H.S. 29, 53
- Turpin, J.A., C.A. Schaeffer, M. Bu, L. Graham, R.W. Buckheit Jr., D. Clanton, W.G. Rice, Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor 29, 269
- Tyring, S.K., see Cirelli, R. 29, 141
- Ussery, M.A., see Black, P.L. 29, 175
- Valenti, P., see Marchetti, M. 29, 221
- Vallet, T., see Biron, F. 29, 111
- Vanagt, W.Y.R., see Stals, F.S. 29, 61
- Vandamme, A.-M., see Esté, J.A. 29, 297
- Vella, S., see Jacobsen, H. 29, 95
- Vella, S., C. Galluzzo, G. Giannini, M.F. Pirillo, I. Duncan, H. Jacobsen, M. Andreoni, L. Sarmati, L. Ercoli, Vila, J., see Biron, F. 29, 111
- Vreese, K.D., D. Reymen, P. Griffin, A. Steinkasserer, G. Werner, G.J. Bridger, J. Esté, W. James, G.W. Henson, Wachsmann, M., B.G. Petty, K.C. Cundy, H.S. Jaffe, P.E. Fisher, A. Pastelak, P.S. Lietman, Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects 29, 153
- Wagenaar, S.S., see Stals, F.S. 29, 61
- Warburg, M., see McLaren, C. 29, 119
- Weiss, H.L., see Whitley, R.J. 29, 67
- Werner, G., see Vreese, K.D. 29, 209
- Whitley, R.J., J.W. Gnann Jr, H.L. Weiss, S.-j. Soong, Short communication Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host 29, 67
- Wittrock, R., see Black, P.L. 29, 175
- Witvrouw, M., see Esté, J.A. 29, 297
- Wong, J.P., see Saravolac, E.G. 29, 199
- Xie, M.-Y., see Faraj, A. 29, 261
- Yang, H., R.L. Drain, C.A. Franco, J.M. Clark, Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice 29, 233

Wittrock, R., see Black, P.L. **29**, 175
Witvrouw, M., see Esté, J.A. **29**, 297
Wong, J.P., see Saravolac, E.G. **29**, 199
Xie, M.-Y., see Faraj, A. **29**, 261

Yang, H., R.L. Drain, C.A. Franco, J.M. Clark,
Efficacy of BMS-180194 against experimental
cytomegalovirus infections in immunocompro-
mised mice **29**, 233